Documentation remains one of the most persistent weaknesses identified during U.S. Food and Drug Administration (…
-
- tel Reach Us: 919-213-9000
Documentation remains one of the most persistent weaknesses identified during U.S. Food and Drug Administration (…
On June 29, the FDA selected seven companies for the first cohort of its PreCheck Pilot Program.
The agency…
Many life sciences projects do not stall because of the wrong strategy. They stall because no one clearly owns the…
A pharmaceutical facility can be on schedule, under construction, and moving through major project milestones while…
The facility is built. The cleanroom is classified. The equipment is installed. And the project is still months…
A written 483 response may be "the primary or a key component" in FDA's evaluation of whether subsequent Agency…
Qualified vendors don’t always lose because of price, scope, or technical ability. Often, they lose momentum…